Pharmacokinetics & metabolism

	VIENET R., BOUVET P. & ISTIN M.
	Cinétique et distribution du 206Bi chez le rat et le lapin : un modèle. The Int. J.Appl. Radiat. Isot. vol 34 nº4, 747-753 (1983).

	EZAN E., DRIEU K., ROUGEOT C. & DRAY F.
	Radioimmunoassay of DTrp6-Luteinizing Hormone Releasing Hormone: its application to pharmacokinetic studies after single injection and long acting formulation administration. Regulatory Peptides. 14, 155-167(1986).

	DRIEU K., DEVISSAGUET J.P., DUBOITESSELIN R., DRAY F. & EZAN E.
	Pharmacokinetics of DTrp6LHRH in man-sustained release polymer microsphere study (i.m. route). Progress in Clinical and Biological Research. 243, 435-438 (1986).

	DEVISSAGUET J., DRIEU K., DRAY F. & EZAN E.
	Pharmacokinetic study of Triptorelin (DTrp6-LHRH), a LHRH analogue in dog and in human following a single injection of an aqueous solution. Gynecological Endocrinology. 2, 109-110 (1988).

	BENECH H. & GROGNET J-M.
	Automatisation de la préparation d'échantillon pour doser des médicaments dans les fluides biologiques. Spectra 2000. 158, 39-42 (1991).

	PEYRONNEAU M-A., RENAUD J-P., TRUAN G., URBAN P., POMPON D. & MANSUY D.
	Optimisation of yeast- expressed human liver 3A4 catalytic activities by coexpressing NADPH-P450 reductase and cytochrome b5. Eur. J. Biochem. 207, 109-116 (1992).

	MANSUY D. & DELAFORGE M.
	Interactions of macrolides with cytochrome P-450 and their clinical relevance. Macrolides, A.Bryskier, J.P.Butzler, H.C.Neu and P.M.Tulkens, vol 47 pp 635-646, Arnette Blackwell. (Eds 1993).

	EZAN E., MORGE X., LELIEVRE E., CREMINON C., PIRAUBE C. & GROGNET J-M.
	Enzyme immunoassay for a new angiotensin converting enzyme inhibitor Zabicipril and its active metabolite in human plasma: application to pharmacokinetics studies. Therapeutic Drug Monitoring. 15, 448-454 (1993).

	GROGNET J-M., CARDE P., ISNARD F., MORGE X., HERRODIN F., EZAN E., PRADELLES Ph., THOMAS F. & DESCHAMPS DE PAILLETTE E.
	Seraspenid : a peptide with hematopoietic regulatory activities. Pharmacokinetics in animals and man. Third International conference on the negative regulation of hematopoietic cell growth and differentiation. In : The negative regulation of hematopoiesis (Ed. Guigon M.). John Libbey Eurotext Ltd. 229, 191-191 (1993).

	PEYRONNEAU M-A., RENAUD J-P., URBAN P., POMPON D. & MANSUY D.
	Expression in yeast of three natural allelic cDNAs coding for human liver P450 3A4: different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. Eur. J. Biochem. 218, 355-361 (1993).

	EZAN E., MORGE X., LELIEVRE E., CRÉMINON C., PIRAUBE C. & GROGNET J-M
	Enzyme immunoassays for a new angiotensin converting enzyme inhibitor zabicipril and its active metabolite in human plasma: application to pharmacokinetic studies. Therapeutic Drug Monitoring. 15, 448-454 (1993).

	RENAUD J-P., PEYRONNEAU M-A., URBAN P., TRUAN G., CULLIN C., POMPON D., BEAUNE P-H. & MANSUY D.
	Recombinant yeast in drug metabolism. Toxicology. 82, 39-52 (1993).

	EZAN E., CARDE P., LE KERNEAU J., ARDOUIN T., THOMAS F., ISNARD F., DESCHAMPS DE PAILLETTE E. & GROGNET J-M.
	Pharmacokinetics in human volunteers and patients of NAC-SDKP, anegative regulator of hematopoiesis. Drug Metabolism and Disposition. 22, 843-848 (1994).

	BENECH H., BRUNE P., PRUVOST A., ARCHIMBAULT Ph., GUILLOT P., MURPHY R., MACLOUF J. & GROGNET J-M.
	Fate of etiproston, a synthetic analogue of PGF2 in cow. J. Vet. Pharm. Therap. 17, 339-344 (1994).

	BENECH H., PRUVOST A., BOURGUIGNON M., THOMAS J-L., MORGE X., RIVIERE R. & GROGNET J-M.
	Study of the bioavailability of an oral form of magnesium in man using two stable isotopes. Magnes. Res. 7, suppl.1, 72 (1994).

	PEYRONNEAU M-A., DELAFORGE M., RIVIERE R., RENAUD J-P. & MANSUY D.
	High affinity of ergopeptides for cytochromes P450 3A: Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur. J. Biochem. 223, 947-956 (1994).

	NICOL P., VIENET R., & COLL.
	Pharmacokinetic, metabolic and antidiarrheal properties of (d and l) haptapeptides of sorbin in rodent. Peptides. Vol. 16, No. 8 pp 1343-135 (1995).

	GIRAULT J-P., GHARBI-BENAROUS J. & DELAFORGE M.
	Structures des macrolides. Conséquences sur la pharmacocinétique et les interactions médicamenteuses. Lettre de l'Infectiologue. 6-9 (1995).

	BENSOUSSAN C., DELAFORGE M. & MANSUY D.
	Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 49, 591-602 (1995).

	LAFARGUE P.,BENECH H., CHAMINADE P., CHEGARAY E., PIÉRARDC., CAMPION J.F. & HENRIC-RESPLANDY M.
	Study of urinary excretion of codeine and morphine after oral ingestion of codeine. Ann. Pharm. Fr. 53(2), 66-74 (1995).

	NICOL P., VIENET R., JOURDAN G., DUMAS C., ABOU EL FADIL F., BENECH H., GROGNET J-M., TARRADE T., PANSU D. & DESCROIX-VAGNE M.
	Pharmacokinetics, metabolic, and antidiarrheal properties of (D and L) heptapeptide of sorbin in rodent. Peptide, 16(8), 1343-1350 (1995).

	BENECH H. & GROGNET J-M.
	Recent data on the evaluation of magnesium bioavailability in human. Magnes. Res. 8(3): 277-284 (1995).

	LAFARGUE P., BENECH H., CHAMINADE P., CHEGARAY E., PIÉRARD C., CAMPION J-F. & HENRIC-RESPLANDY M.
	Study of urinary excretion of codeine and morphine after oral ingestion of codeine. Ann. Pharm. Fr. 53(2), 66-74 (1995).

	NICOL P., VIENET R., JOURDAN G., DUMAS C., ABOU EL FADIL F., BENECH H., GROGNET J-M., TARRADE T., PANSU D. & DESCROIX-VAGNE M.
	Pharmacokinetics, metabolic, and antidiarrheal properties of (D and L) heptapeptide of sorbin in rodent. Peptide. 16(8): 1343-1350 (1995).

	BENECH H., PRUVOST A., BOURGUIGNON M., THOMAS J-L.; MORGE X., RIVIERE R. & GROGNET J-M.
	Bioavailability of magnesium in man using two stable isotopes. Current Research in Magnesium, edited by M.J. Halpern and J. Durlach. John Libbey & Company Ltd. (1996).

	EZAN E., ARDOUIN T., DELHOTAL-LANDES B., FLOUVAT, HANSLIK T., LEGEAI J-M. & GROGNET J-M.
	Bioequivalence of alpha-dihydroergocryptine : utility of metabolite evaluation. International Journal of Clinical Pharmacology Therapy and Toxicology. 34, 32-37 (1996).

	LI Q., LOU X., PEYRONNEAU M-A., STRAUB P-O. & TUKEY R-H.
	Expression and functional domains of rabbit liver UDP-glucuronosyltransferase 2B16 and 2B13. J. Biol. Chem. Feb 7, 272(6):3272-3279 (1997).

	VALENTE D., DELAFORGE M., GUIVARC'H D., VIENET R., GROGNET J-M. & EZAN E.
	Metabolite involvement in bromocriptine-induced prolactin inhibition. The Journal of Pharmacology and Experimental Therapeutics. 282, 1418-1424 (1997).

	RENODON A., J-L. BOUCHER, SARI M-A., DELAFORGE M., OUAZZZANI J. & MANSUY D.
	Bromokriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. FEBS Letters. 406, 33-36 (1997).

	USTOT J., MOALI C., BROLLO M., BOUCHER J-L., DELAFORGE M., MANSUY D., TENU J-P. & ZIMMERMANN J-L.
	The new a Amino acid N w hydroxy-nor-L-arginine: a high-affinity inhibitor of arginase well adapted to bind to its manganese cluster. J. Am. Chem. Soc. 119, 4086-4087 (1997).

	RENODON A., BOUCHER J-L., SARI M-A., DELAFORGE M., OUAZZZANI J. & MANSUY D.
	Strong inhibition of neuronal nitric oxide synthase by the calmodulin antagonist and anti-estrogen drug tamoxifen. Biochem. Pharmacol. 54, 1109-1114 (1997).

	DELAFORGE M., ANDRÉ F., JAOUEN M., DOLGOS H., BENECH H., GOMIS J-M., NOEL J-P., CAVELIER F., VERDUCCI J. & AUBAGNAC J-L.
	Bromokriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. FEBS Letters. 406, 33-36 (1997).

	COLIN S., MASCARELLI F., JEANNY JC., VIENET R., BOUCHE G., COURTOIS Y. & LABARRE J.
	Comparative study in vivo and in vitro of uniformly C-14 labelled and I-125 labelled recombinant fibroblast growth factor 2. Eur. J. Biochem. (1997).

	DELAFORGE M., ANDRÉ F., JAOUEN M., DOLGOS H., BENECH H., GOMIS J-M., NOËL J-P., CAVELIER F., VERDUCCI J., AUBAGNAC J-L. & LIEBERMANN B.
	Metabolism of tentoxin and related compounds by hepatic cytochrome P450 isoenzymes. Eur. J. Biochem. 250, 150-157(1997).

	BENECH H., VINCENTI M., FOUCHART F., PRUVOST A., VIENET R., ISTIN M. & GROGNET J.M.
	Development and in vivo assessment of a transdermal system for physostigmine. Meth Find Exp Clin Pharmacol. 20 (6): 489-498 (1998).

	GOUJON L., BROSSETTE T., DEREUDRE-BOSQUET N., CREMINON C., CLAYETTE P., DORMONT D., MIOSKOWSKI C., LEBEAU L. & GRASSI J.
	Monitoring of intracellular levels of 5'-Monophosphate-AZT using an enzyme immunoassay. J. Immunol. Meth. In press (1998).

	RENOUF S., DUROCHER A., VALENTE D., GROGNET J-M. & EZAN E.
	Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum. European Journal of Drug Pharmacokinetics and Metabolism. In press (1998).

	BERTHO G., GHARBI-BENAROUS J., DELAFORGE M., LANG C., PARENT A. & GIRAULT J-P.
	Conformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomes. J. Med. Chem. 41, 3373-3386 (1998).

	BENECH H, PRUVOST A, BATEL A, BOURGUIGNON M, THOMAS J-L. & GROGNET J-M.
	Use of the stable isotope technique to evaluate the bioavailability of a pharmaceutical form of magnesium. Pharm. Res. 15, 2, 351-355 (1998).

	COLIN S., JEANNY JC., MASCARELLI F., VIENET R., AL-MAHMOOD S., COURTOIS Y. & LABARRE J.
	In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalisation and catabolism of exogenous basic fibroblast growth factor Molecular Pharmacology. 1, 74-82 (1999).

| Back to Scientific Section Page |